Quantcast

Latest Intarcia Therapeutics Inc. Stories

2014-09-19 08:25:27

-- Patients treated with ITCA 650 for 6 months showed an average HbA1c reduction of -3.2% at the time of the interim analysis; patients at baseline had HbA1c greater than or equal to 10% to 12%. VIENNA, Sept. 19, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the presentation of positive interim clinical data for its lead candidate ITCA 650 (continuous subcutaneous delivery of exenatide) in type 2 diabetes patients with high baseline HbA1c levels at the 50(th) Annual Meeting...

2014-09-17 08:29:46

- Data indicate 58% non-adherence to second-line treatments in T2D patients, significantly higher than patients report and prescribers perceive VIENNA, Sept. 17, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the presentation of compelling, quantitative data from a study of the cost and predictability of non-adherence in type 2 diabetes therapies at the 50(th) Annual Meeting of the European Association for the Study of Diabetes (EASD). In a poster session today, Christian...

2014-09-11 16:28:19

- Oral presentation 9/19: interim Phase 3 results for ITCA 650 among patients with high baseline (HBL) HbA1c levels between 10-12% showed dramatic HbA1c reductions, even in patients with high HbA1c despite multi-drug therapy BOSTON, Sept. 11, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced its participation in the 50(th) Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place in Vienna September 15 -19. Intarcia's lead product...

2014-08-05 08:35:45

- Zalani joins Intarcia to drive the strategic and operational direction of Intarcia's Global Regulatory and Quality efforts with health authorities, partners and external stakeholders - BOSTON, Aug. 5, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today officially announced the appointment of Sunita Zalani, Ph.D., as Vice President and Global Head of Regulatory Affairs and Quality. In her new capacity, Dr. Zalani serves on the Leadership Team and reports directly to Chairman,...

2014-06-15 08:21:29

-- The average HbA1C reductions in patients treated with ITCA 650 for 6 months at the time of the interim analysis were -3.2%; patients at baseline had HbA1C levels between 10-12%. BOSTON, June 15, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the highlights of a poster presentation at the 74(th) Scientific Sessions of the American Diabetes Association (ADA) held in San Francisco that contained the first 6-month data from an ongoing open-label phase 3 trial...

2014-04-01 08:28:59

-Promising first interim phase 3 data for ITCA 650 in type 2 diabetes, combined with robust execution against key milestones and the addition of key talent BOSTON, April 1, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the completion of another landmark private round of equity financing for $200 million. Together with the $210 million round of equity and debt financing in November of 2012 the company is very strongly positioned for future milestones and launch...

2014-02-26 08:30:09

- Smith takes-on innovative CXO role to optimize customer experiences and consistently deliver the best possible outcomes for patients, payors and providers - BOSTON, Feb. 26, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today formally announced the appointment of Jay Smith as Head of Customer Experience & Outcomes (CXO), an officer level position for which there is no precedent or analogue in the Bio-Pharma industry. The role focuses on one of the highest priorities within...

2014-01-13 08:29:42

- Highlights will include first interim phase 3 data for ITCA 650, the Company's novel once or twice-yearly GLP-1 receptor agonist for type 2 diabetes. Data will show up to six months of treatment results from Intarcia's global Phase 3 clinical trial program known as FREEDOM - BOSTON, Jan. 13, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced that Chairman, President and CEO Kurt Graves will present a Company overview today at the J.P. Morgan 32nd Annual Healthcare...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related